经皮三叉神经刺激治疗持续性特发性面痛:病例系列
本研究回顾性分析了23例接受经皮三叉神经刺激(TNS)治疗的持续性特发性面痛(PIFP)患者,20例(86.9%)在试验刺激后报告疼痛改善超过50%。植入永久装置且有VAS评分的13/17例(76.4%)患者,平均VAS评分从术前5.69±2.09降至术后0.15±0.55(P=0.0014),9例患者吗啡等效用量亦显著减少。
要点
- 23例PIFP患者接受经皮TNS,20例(86.9%)试验刺激后疼痛改善>50%。
- 永久植入且有VAS数据的13例患者,VAS从5.69±2.09降至0.15±0.55(P=0.0014)。
- 9例患者吗啡等效用量从50.54±51.30降至25.83±33.58(P=0.048)。
核心结论
- 经皮三叉神经刺激对持续性特发性面痛具有疗效,并可显著减少吗啡等效用量。
- 作者指出需要进一步纵向研究验证上述结果。
研究设计与样本
- 回顾性病历审查,纳入就诊于Emory University Hospital并接受TNS治疗的PIFP患者,共23例。
- 主要结局为术后视觉模拟量表(VAS)疼痛评分和吗啡等效用量。
- 采用描述性统计、均值±标准差及非参数Wilcoxon符号秩检验,P<0.05为有统计学意义。
主要发现
- 23例中20例(86.9%)在试验刺激后报告疼痛改善>50%。
- 接受永久TNS植入且有VAS评分的13/17例(76.4%)患者,平均术前VAS 5.69±2.09 vs 术后0.15±0.55(P=0.0014)。
- 9例有数据的患者吗啡等效用量术前50.54±51.30 vs 术后25.83±33.58(P=0.048)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Persistent idiopathic facial pain (PIFP) can be refractory to conventional management approaches. Neuromodulatory procedures such as percutaneous trigeminal nerve stimulation (TNS) have been sparsely reported as potential treatment options for amelioration of debilitating refractory pain associated with PIFP. The present study investigated the use of percutaneous TNS in a series of patients with PIFP to evaluate the potential efficacy of pain relief. METHODS: We performed a retrospective medical record review for patients with PIFP who had presented to Emory University Hospital and had undergone TNS for PIFP. The primary outcomes were postoperative pain using the visual analog scale (VAS) for pain and morphine equivalent use. Descriptive statistics, mean ± standard deviation, and the nonparametric Wilcoxon sign rank test were used, as appropriate. A P value of <0.05 was considered statistically significant. RESULTS: A total of 23 patients underwent percutaneous TNS for PIFP. Of the 23 patients, 20 (86.9%) reported a >50% improvement after trial stimulation. Of the patients who had received permanent TNS implants, 13 of 17 (76.4%) had VAS scores available. For these patients, the mean preoperative VAS score had decreased from 5.69 ± 2.09 to 0.15 ± 0.55 postoperatively. The VAS scores displayed a statistically significant decrease after TNS (P = 0.0014). A subset of 9 patients with available data also demonstrated a significant reduction in morphine equivalent use after TNS (before, 50.54 ± 51.30; after, 25.83 ± 33.58; P = 0.048). CONCLUSION: The results from the present study have indicated that percutaneous stimulation of the trigeminal nerve is efficacious in the treatment of PIFP and can significantly decrease morphine equivalent use. Further longitudinal studies are required to validate our results.
引用
- McMahon JT, Tora MS, Bentley JN, et al. Percutaneous Trigeminal Nerve Stimulation for Persistent Idiopathic Facial Pain: A Case Series. World Neurosurg. 2019. PMID: 30902776. doi:10.1016/j.wneu.2019.03.107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。